Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell infusion for steroid-resistant acute graft-versus-host disease or poor graft function
NL-OMON31471Phase 2Withdrawn
- Sponsor
- Maastricht University Medical Center+
- Start
- Sep 2008
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mesenchymal stem cells in Acute Graft-Versus-Host Disease (aGvHD), poor graft function (PGF) and mixed donor T-cell chimerism (MDTC) (3 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Efficacy in steroid-refractory acute GVHD, Efficacy in poor graft function and 1 more. Planned start Sep 2008; status: withdrawn.
02
Drugs
mesenchymal stem cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)poor graft function (PGF)mixed donor T-cell chimerism (MDTC)
Beyond the preview
Go deeper on NL-OMON31471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31471.